Kangwon, South Korea

Yung-Hi Kim

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Biosynergen, Inc.. Active years: 2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yung-Hi Kim. Retrieved from https://idiyas.com/inventor/yung-hi-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0



Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yung-Hi Kim: Innovator in Therapeutic Applications

Introduction

Yung-Hi Kim is a notable inventor based in Kangwon-do, South Korea. He has made significant contributions to the field of therapeutics, particularly through his innovative research on G2A receptor agonist ligands. His work focuses on addressing diseases associated with neutrophil accumulation and hyperactivity.

Latest Patents

Yung-Hi Kim holds 1 patent for his invention titled "Therapeutic use of agonist ligands specific to G2A receptor." This patent describes novel therapeutic methods for treating diseases linked to neutrophil activity and microbial infections. The invention involves administering LPC (lysophosphatidylcholine), SPC (sphingophosphorylcholine), or their derivatives to effectively manage inflammatory diseases and ischemia-reperfusion injuries.

Career Highlights

Throughout his career, Yung-Hi Kim has worked with various companies, including Biosynergen, Inc. and Arimed Inc. His expertise in therapeutic applications has positioned him as a valuable contributor to the field of medical research.

Collaborations

Yung-Hi Kim has collaborated with notable colleagues such as Dong-Keun Song and Hong-Won Suh. These partnerships have further enhanced his research and development efforts in therapeutic innovations.

Conclusion

Yung-Hi Kim's contributions to the field of therapeutics through his innovative patent on G2A receptor agonist ligands highlight his commitment to advancing medical science. His work continues to pave the way for new treatment options for inflammatory diseases and infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…